Vimarsana
Biggest News Aggregation in the World

Page 3 - Oncodesign Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncodesign Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncodesign Services Today - Breaking & Trending Today

Preclinical agents development against lung fibrosis - Vimarsana News

Preclinical agents development against lung fibrosis

This article describes the challenges in the preclinical development of therapeutic agents against lung fibrosis.

Dive into the reasons behind preclinical cancer models failure - Vimarsana News

Dive into the reasons behind preclinical cancer models failure

This article dives into the details behind the failure of the preclinical cancer models, reasons,consequences and potential solutions.

Kinase Inhibitors for Inflammatory Diseases: Preclinical Development, Upcoming Webinar Hosted by Xtalks - Vimarsana News

Kinase Inhibitors for Inflammatory Diseases: Preclinical Development, Upcoming Webinar Hosted by Xtalks

Toronto, ON (PRWEB) May 25, 2023 -- Protein kinases act as master regulators of multiple key processes within the cell cycle, and aberrant regulation of their

Source: prweb.com
Preclinical Models for the Identification of Chemotherapy Predictive Signatures in Pancreatic Cancer, Upcoming Webinar Hosted by Xtalks - Vimarsana News

Preclinical Models for the Identification of Chemotherapy Predictive Signatures in Pancreatic Cancer, Upcoming Webinar Hosted by Xtalks

Toronto, ON (PRWEB) April 26, 2023 -- Currently, chemotherapy is the primary mode of treatment for pancreatic ductal adenocarcinoma (PDAC), a highly

Source: prweb.com
OPM Announces Its 2022 Annual Results and Provides an Update on Its Clinical Developments - Vimarsana News

OPM Announces Its 2022 Annual Results and Provides an Update on Its Clinical Developments

Revenues and operating income in 2022 of €8.3 M (+110% vs. 2021 proforma), including revenues of €8 M, mainly driven by a €7 M milestone and a €0.5 M up-frontNet income almost at break-even (€0.2) MStrong financial visibility with a cash position of €13.4 M ensuring the development of our programs for the coming yea...